La Jolla Pharmaceutical Profit Margin

The latest profit margin for LJPC is 3.27% as of June 2022. That compares with 4.15% in the prior-year period — down 21.1% year over year. That is below the Healthcare sector average of 13.71%. Investors often review this figure alongside La Jolla Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, LJPC's profit margin moved from 4.15% to 3.27% — a 21.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in La Jolla Pharmaceutical's valuation or profitability profile.

Against Healthcare companies, LJPC currently prints 3.27% for profit margin, while the sector average sits near 13.71%. That is roughly 76.1% below the sector mean. Large gaps often invite a closer look at La Jolla Pharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively La Jolla Pharmaceutical converts resources into returns. At 3.27%, LJPC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 4.15% in the prior-year period — down 21.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LJPC's profit margin (3.27%), review year-over-year change from 4.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.